team work

2 Houston blockchain companies connect on ESG initiative

These two innovators have linked up for a new ESG offering. Photos courtesy

Two Houston-based startups specializing in blockchain technology have announced a collaborative within the Environmental, Social and Governance, or ESG, space.

Data Gumbo and Topl have partnered up to offer companies a private-public blockchain solution for ESG reporting. The collaborative solution, according to a news release, allows for public-facing, accurate, and immutable ESG progress reports that are accessible to outside audiences and stakeholders, including public analysts, investors, governments, and more.

"As companies today face mounting pressure to report timely and accurate ESG data, including performance and progress, they need the right tools to collect, standardize and automate reporting while preserving security for sensitive data," says Andrew Bruce, CEO and founder of Data Gumbo, in the release. "For the first time, this partnership offers companies total control of their accurate ESG data, allowing them to publish and report metrics in whatever manner best suits them satisfying investors', regulator agencies' and other stakeholders' desires."

The tool will gather business operation and transaction data and compare it to defined standards. This enables the complete review and certification of ESG metrics by auditors using GumboNet ESG. Once the environmental impact is determined, the company can easily share data recorded on Topl's public-facing blockchain.

"Companies can now comprehensively collect ESG data and report to private entities and public audiences," says Kim Raath, founder and CEO of Topl. "This partnership combines the power of our two complementary solutions to support a new level of transparency for companies that desire to showcase their fully verifiable progress on crucial ESG metrics."

Both companies have been players within the ESG space. Data Gumbo launched GumboNet ESG, a sustainability measurement solution that can pull together a company's operational data to ESG standards reporting, in March. Topl's blockchain-as-a-service offering rolled out just a few weeks later.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News